Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript March 3, 2026Arcturus Therapeutics Holdings Inc. misses on earnings expectations.
Arcturus Therapeutics Holdings Inc. (ARCT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 2,611,099 | $16,006,036 | +40% | 0.11% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 511,043 | $3,132,694 | +1228% | 0.01% |
| 3. | Millennium Management Israel Englander | 304,777 | $1,868,283 | +666% | 0% |
| 4. | Point72 Asset Management Steve Cohen | 222,163 | $1,361,859 | 0% | |
| 5. | 120,700 | $739,891 | +444% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.56 | 1,238 | $20,498.80 | 221,764 | 2025-08-15 | Filing | |
| $16.56 | 1,238 | $20,498.80 | 221,764 | 2025-08-15 | Filing | |
| $18.00 | 2,222 | $39,996.00 | 24,942 | 2022-12-15 | Filing | |
| $16.51 | 5,000 | $82,550.00 | 1,480,097 | 2022-11-23 | Filing | |
| $33.33 | 450 | $14,998.50 | 950 | 2020-06-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 12,000 | $249,121.20 | 435,334 | 2024-10-15 | Filing | |
| $32.03 | 50,000 | $1,601,500.00 | 220,526 | 2024-06-12 | Filing | |
| $45.00 | 114 | $5,130.00 | 447,334 | 2024-06-05 | Filing | |
| $40.01 | 26,000 | $1,040,234.00 | 447,448 | 2024-06-03 | Filing | |
| $35.02 | 17,435 | $610,573.70 | 473,448 | 2024-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,138 | $217,225 | 0.21% | |
| 2. | 2,188 | $16,891 | 0% | |
| 3. | 1,506 | $11,626 | 0% | |
| 4. | 653 | $5,041 | 0% | |
| 5. | 329 | $2,583 | 0% |
News See All
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating
On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc.
11 High Growth Micro-cap Stocks to Buy
Investing in stocks of companies with market values under $300 million, otherwise known as micro-cap stocks, offers a unique opportunity to get in early on fast-growing businesses.
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript November 10, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript August 11, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript May 12, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript March 6, 2025Arcturus Therapeutics Holdings Inc. misses on earnings expectations.